Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
Abstract The current study established the first in vitro Encorafenib resistance protocol in BRAF-mutated malignant melanoma (MM) cells and investigated the resistance-related mechanisms. After establishing Encorafenib-resistant A375-MM cells, resistant-related mechanisms were investigated using WST...
Saved in:
Main Authors: | Ceyda Colakoglu Bergel, Isil Ezgi Eryilmaz, Gulsah Cecener, Unal Egeli |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86874-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01) -
Magnolol induces cell death through PI3K/Akt‐mediated epigenetic modifications boosting treatment of BRAF‐ and NRAS‐mutant melanoma
by: Abdullah Al Emran, et al.
Published: (2019-03-01) -
Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
by: Xing Luo, et al.
Published: (2025-01-01) -
RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
by: Bello Abdullahi Umar, et al.
Published: (2019-12-01) -
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance
by: Peng Zhao, et al.
Published: (2025-01-01)